Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
BACKGROUND: All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of treatment with arsenic trioxide with or without ATRA have shown high efficacy and reduced hematologic toxicity. METHODS: We conducted a phase 3, multicenter trial comparing ATRA plus chemotherapy with ATRA plus arsenic trioxide in patients with APL classified as low-to-intermediate risk (white-cell count, ≤10×10(9) per liter). Patients were randomly assigned to receive either ATRA plus arsenic trioxide for induction and consolidation therapy or standard ATRA-idarubicin induction therapy followed by three cycles of consolidation therapy with ATRA plus chemotherapy and maintenance therapy with low-dose chemotherapy and ATRA. The study was designed as a noninferiority trial to show that the difference between the rates of event-free survival at 2 years in the two groups was not greater than 5%. RESULTS: Complete remission was achieved in all 77 patients in the ATRA-arsenic trioxide group who could be evaluated (100%) and in 75 of 79 patients in the ATRA-chemotherapy group (95%) (P=0.12). The median follow-up was 34.4 months. Two-year event-free survival rates were 97% in the ATRA-arsenic trioxide group and 86% in the ATRA-chemotherapy group (95% confidence interval for the difference, 2 to 22 percentage points; P<0.001 for noninferiority and P=0.02 for superiority of ATRA-arsenic trioxide). Overall survival was also better with ATRA-arsenic trioxide (P=0.02). As compared with ATRA-chemotherapy, ATRA-arsenic trioxide was associated with less hematologic toxicity and fewer infections but with more hepatic toxicity. CONCLUSIONS: ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL. (Funded by Associazione Italiana contro le Leucemie and others; ClinicalTrials.gov number, NCT00482833.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,602
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Self-citationCreutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4326 · Cited by 1,735
Self-citationShen, Z.-X., Chen, G.-Q., Ni, J.-H., Li, X.-S., Xiong, S.-M., Qiu, Q.-Y., Zhu, J., Tang, W., Sun, G.-L., Yang, K.-Q., et al. (1997) · Blood · doi:10.1182/blood.v89.9.3354 · Cited by 1,428
Gabert, J., Beillard, E., van der Velden, V. H. J., Bi, W., Grimwade, D., Pallisgaard, N., Barbany, G., Cazzaniga, G., Cayuela, J. M., Cavé, H., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403135 · Cited by 1,284
Acute promyelocytic leukemia: from highly fatal to highly curable
Wang, Z.-Y., & Chen, Z. (2008) · Blood · doi:10.1182/blood-2007-07-102798 · Cited by 1,277
van Dongen, J., Macintyre, E., Gabert, J., Delabesse, E., Rossi, V, Saglio, G., Gottardi, E., Rambaldi, A., Dotti, G., Griesinger, F., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401592 · Cited by 1,169
Self-citationSanz, M. A., Grimwade, D., Tallman, M. S., Lowenberg, B., Fenaux, P., Estey, E. H., Naoe, T., Lengfelder, E., Büchner, T., Döhner, H., et al. (2009) · Blood · doi:10.1182/blood-2008-04-150250 · Cited by 947
Self-citationUnited States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
Soignet, S. L., Frankel, S. R., Douer, D., Tallman, M. S., Kantarjian, H., Calleja, E., Stone, R. M., Kalaycio, M., Scheinberg, D. A., Steinherz, P., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3852 · Cited by 826 · cited 1×
“A genetic diagnosis could be established by detection of the PML-RARA fusion gene by means of reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay,28,29 demonstration of the t(15;17) translocation by means of conventional karyotyping or fluorescence in situ hybridization (FISH),30 or evidence of a microspeck…”
Research works printed but not linked: 3
- Zhang P, 1996, Chin J Hematol, 17, 58
- Sanz MA, 2000, Blood, 96, 1247
- Grimwade D, 2000, Blood, 96, 1297
Cited by
Items 101–200 of 1,000
From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm
Adashek, J. J., Subbiah, V., & Kurzrock, R. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.08.009 · Cited by 103
Acute myeloid leukemia in children: Current status and future directions
Taga, T., Tomizawa, D., Takahashi, H., & Adachi, S. (2015) · Pediatrics International · doi:10.1111/ped.12865 · Cited by 101
Wang, C., Zhang, W., He, Y., Gao, Z., Liu, L., Yu, S., Hu, Y., Wang, S., Zhao, C., Li, H., et al. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00980-7 · Cited by 99
Sun, H., Lin, D., Guo, X., Masouleh, B. K., Gery, S., Cao, Q., Alkan, S., Ikezoe, T., Akiba, C., PAQUETTE, R. L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7702 · Cited by 107
“Treatment of acute promyelocytic leukemia (APL) with AS 2 O 3 has unique favorable cure rates [79], and the major mechanism of action is through the degradation of PML-RARα, the driver of APL [80].”
BackgroundModulation of dysregulated cancer metabolism by plant secondary metabolites: A mechanistic review
Fakhri, S., Moradi, S. Z., Farzaei, M. H., & Bishayee, A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.007 · Cited by 106
Efficace, F., Gaïdano, G., & Lo‐Coco, F. (2017) · Blood · doi:10.1182/blood-2017-03-737403 · Cited by 98
Self-citationAcute myelogenous leukemia in adolescents and young adults
Creutzig, U., Kutny, M. A., Barr, R. D., Schlenk, R. F., & Ribeiro, R. C. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27089 · Cited by 98
Self-citationManagement of patients with acute promyelocytic leukemia
Käyser, S., Schlenk, R. F., & Platzbecker, U. (2018) · Leukemia · doi:10.1038/s41375-018-0139-4 · Cited by 97
Self-citationEnane, F. O., Saunthararajah, Y., & Korc, M. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0919-9 · Cited by 101
Loo, S. Y., Toh, L. P., Xie, W. H., Pathak, E., Tan, W. W. S., Ma, S., Lee, M. Y., Shatishwaran, S., Yeo, J. Z. Z., Yuan, J. X., et al. (2021) · Science Advances · doi:10.1126/sciadv.abh2443 · Cited by 99
“In APL and cutaneous T cell lymphoma, retinoids have been applied as a first-line adjuvant with curative intent ( 49 ).”
Chen, J., Jin, Z., Zhang, S., Zhang, X., Li, P., Yang, H., & Ma, Y. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00956-0 · Cited by 104
“ATO is widely used in first-line therapies for newly diagnosed and relapsed acute promyelocytic leukemia (APL), either alone or in combination with all-trans retinoic acid (ATRA), which revolutionarily makes this lethal malignant disease curable [27, 28].”
BackgroundAutophagy in acute leukemias: A double-edged sword with important therapeutic implications
Evangelisti, C., Evangelisti, C., Chiarini, F., Lonetti, A., Buontempo, F., Neri, L. M., McCubrey, J. A., & Martelli, A. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.09.023 · Cited by 106
A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
Guenther, L. M., Dharia, N. V., Ross, L. S., Conway, A. S., Robichaud, A. L., Catlett, J. L., Wechsler, C. S., Frank, E. S., Goodale, A. B., Church, A. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0372 · Cited by 100
“In some select instances, such as in the treatment of chronic myelogenous leukemia (CML) and acute promyelocytic leukemia (APML), targeted therapies have even replaced standard cytotoxic medications (2).”
BackgroundPharmacological reactivation of p53 in the era of precision anticancer medicine
Tuval, A., Strandgren, C., Heldin, A., Palomar-Siles, M., & Wiman, K. G. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00842-2 · Cited by 93
“Arsenic trioxide has several toxicities including nephrotox-icity, hepatotoxicity and, occasionally, fatal cardiac arrhythmias 112,113 .”
Sumoylation in Physiology, Pathology and Therapy
Şahin, U., de Thé, H., & Lallemand-Breitenbach, V. (2022) · Cells · doi:10.3390/cells11050814 · Cited by 103
Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia
McKenzie, M. D., Ghisi, M., Oxley, E. P., Ngo, S., Cimmino, L., Esnault, C., Liu, R., Salmon, J. M., Bell, C. C., Ahmed, N., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.07.001 · Cited by 91
Roboz, G. J., Ritchie, E. K., Carlin, R. F., Samuel, M., Gale, L., Provenzano, J. L., Curcio, T. J., Feldman, E. J., & Kligfield, P. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.2913 · Cited by 99
Kutny, M. A., Alonzo, T. A., Gerbing, R. B., Wang, Y.-C., Raimondi, S. C., Hirsch, B. A., Fu, C. H., Meshinchi, S., Gamis, A. S., Feusner, J. H., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6183 · Cited by 90
“8) Platelet count, median (range) 18 (3-48) 19 (3-198) 24 (5-107) 21.”
Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges
Sun, G., Rong, D., Li, Z., Sun, G., Wu, F., Li, X., Cao, H., Cheng, Y., Tang, W., & Sun, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.694363 · Cited by 91
Esposito, M. T., & So, C. W. E. (2014) · Chromosoma · doi:10.1007/s00412-014-0482-9 · Cited by 95
“ATRA reverses the transcriptional block and is a key weapon for targeted therapy of APL (Fung and So 2013; Lo-Coco et al. 2013).”
BackgroundInfluentialα-ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis
Atlante, S., Visintin, A., Marini, E., Savoia, M., Dianzani, C., Giorgis, M., Sürün, D., Maione, F., Schnütgen, F., Farsetti, A., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0802-8 · Cited by 94
Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes
Saunthararajah, Y., Sekeres, M. A., Advani, A. S., Mahfouz, R. Z., Durkin, L. M., Radivoyevitch, T., Englehaupt, R. K., Juersivich, J., Cooper, K., Husseinzadeh, H. D., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78789 · Cited by 91
“Suppression of myeloid cancer clones, even if by noncytotoxic differentiation (28, 57), suppresses contributions of cancer clones to circulating blood counts and causes nadirs, which occurred between weeks 6 and 11 in the present study.”
Jillella, A. P., & Kota, V. K. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.09.001 · Cited by 85
“Recent paradigm shifting studies, the PETHEMA LPA 96 and LPA 99, GIMEMA-GAAMLSG (APL0406 trial) and Australasian Leukemia Group multicenter trial (APML4) used prophylactic doses of prednisone or dexamethasone to prevent DS and used treatment doses for symptoms suggestive of established DS [2,4,5].”
Cicconi, L., Divona, M., Ciardi, C., Ottone, T., Ferrantini, A., Lavorgna, S., Alfonso, V., Paoloni, F. P., Piciocchi, A., Avvisati, G., et al. (2016) · Leukemia · doi:10.1038/leu.2016.122 · Cited by 84
Self-citationDaver, N. G., Kantarjian, H. M., Marcucci, G., Pierce, S. A., Brandt, M., Dinardo, C. D., Pemmaraju, N., Garcia‐Manero, G., O'Brien, S. M., Ferrajoli, A., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.13189 · Cited by 86
“Lo-Coco et al (2013) have shown the efficacy and safety of ATRA in combination with ATO in patients with low-tointermediate risk APL.”
BackgroundLeukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia
Laverdière, I., Boileau, M., Neumann, A. L., Frison, H., Mitchell, A., Ng, S., Wang, J. C. Y., Minden, M. D., & Eppert, K. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0087-2 · Cited by 90
Targeting chromatin complexes in fusion protein-driven malignancies
Brien, G. L., Stegmaier, K., & Armstrong, S. A. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0132-x · Cited by 86
Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients
Testa, U., & Lo‐Coco, F. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2622-1 · Cited by 81
Self-citationThe European Hematology Association Roadmap for European Hematology Research: a consensus document
Engert, A., Balduini, C., Brand, A., Coiffier, B., Cordonnier, C., Dohner, H., de Wit, T. D., Eichinger, S., Fibbe, W., Green, T., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.136739 · Cited by 81
Self-citationUnderstanding the molecular pathogenesis of acute promyelocytic leukemia
Lo‐Coco, F., & Hasan, S. K. (2014) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2014.04.006 · Cited by 82
“Acute promyelocytic leukemia (APL) represents one of the best paradigms of successful targeted therapy by providing the first example of chemotherapy-free cure of acute leukemia [1].”
BackgroundSelf-citationNucci, M., & Anaissie, E. J. (2014) · Blood · doi:10.1182/blood-2014-04-516211 · Cited by 81
Current Management of Childhood Acute Myeloid Leukemia
Rubnitz, J. E. (2016) · Pediatric Drugs · doi:10.1007/s40272-016-0200-6 · Cited by 79
“Based on the successful removal of conventional chemotherapy in adults with standard-risk APL [67], the primary aims of the”
BackgroundInfluentialRetinoic Acid Receptors in Acute Myeloid Leukemia Therapy
di Martino, O., & Welch, J. S. (2019) · Cancers · doi:10.3390/cancers11121915 · Cited by 85
“PML-RARA binds the HDAC complex with higher affinity than the RARA-RXR heterodimer, causing a block of differentiation at the promyelocytic stage due to gene transcription repression [92].”
BackgroundInfluentialEfficace, F., Mandelli, F., Avvisati, G., Cottone, F., Ferrara, F., Bona, E. D., Specchia, G., Breccia, M., Levis, A., Sica, S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.3453 · Cited by 78
Self-citationTreating Leukemia in the Time of COVID-19
Paul, S., Rausch, C. R., Jain, N., Kadia, T. M., Ravandi, F., Dinardo, C. D., Welch, M. A., Dabaja, B. S., Daver, N. G., Garcia‐Manero, G., et al. (2020) · Acta Haematologica · doi:10.1159/000508199 · Cited by 80
Zhang, M., Xue, Y., Zheng, B., Li, L., Chu, X., Zhao, Y., Wu, Y., Zhang, J., Han, X., Wu, Z., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112167 · Cited by 79
Centritto, F., Paroni, G., Bolis, M., Garattini, S. K., Kurosaki, M., Barzago, M. M., Zanetti, A., Fisher, J. N., Scott, M. F., Pattini, L., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404670 · Cited by 82
“ATRA (all-trans retinoic acid) is used in the management of acute promyelocytic leukemia (Tallman et al , 1997; Lo-Coco et al , 2013), and the retinoid holds promise for the treatment of solid tumors like breast cancer (Garattini et al , 2014).”
Estey, E. H., Levine, R. L., & Löwenberg, B. (2015) · Blood · doi:10.1182/blood-2015-01-561373 · Cited by 85
Lucena-Araujo, A. R., Kim, H. T., Jácomo, R. H., Melo, R. A. M., Bittencourt, R., Pasqüini, R., Pagnano, K. B. B., Fagundes, E. M., Chauffaille, M. D. L., CHIATTONE, C. S., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2142-9 · Cited by 77
“Furthermore, based on the independent effect of arsenic trioxide (ATO) on the retinoic acid signaling pathway [53, 54], it would be interesting to test whether APL treatment based on ATRA combined with ATO [55] would overcome the adverse prognosis of FLT3-ITD mutations.”
BackgroundSelf-citationRetinoic acid signaling in cancer: The parable of acute promyelocytic leukemia
Ablain, J., & de Thé, H. (2014) · International Journal of Cancer · doi:10.1002/ijc.29081 · Cited by 76
“Yet, recent clinical trials have demonstrated the overwhelming superiority of a frontline combination of the two drugs without any DNAdamaging chemotherapy.(95,96) This treatment cures 95% of the patients with APL with limited toxicity, providing the most striking example of successful targeted therapy in cancer.”
BackgroundMcCulloch, D., Brown, C. M., & Iland, H. J. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s100513 · Cited by 82
Mitochondrial metabolism as a target for acute myeloid leukemia treatment
Panina, S., Pei, J., & Kirienko, N. V. (2021) · Cancer & Metabolism · doi:10.1186/s40170-021-00253-w · Cited by 88
“Targeting complex III may also be productive.”
BackgroundInfluentialLengfelder, E., Lo‐Coco, F., Adès, L., Montesinos, P., Grimwade, D. J., Kishore, B., Ramadan, S. M., Pagoni, M. N., Breccia, M., Huerta, A. J. G., et al. (2015) · Leukemia · doi:10.1038/leu.2015.12 · Cited by 74
Self-citationThe Leukemias: A Half-Century of Discovery
Freireich, E. J., Wiernik, P. H., & Steensma, D. P. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1034 · Cited by 91
Paulson, K., Serebrin, A., Lambert, P. J., Bergeron, J., Everett, J., Kew, A. K., Jones, D., Mahmud, S. M., Meloche, C., Sabloff, M., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12931 · Cited by 73
“The combination of ATRA with anthracycline-based chemotherapy or arsenic trioxide (ATO) results in resolution of the coagulopathy, high complete remission (CR) rates, and excellent overall survival (OS) (Sanz et al, 2009; Lo-Coco et al, 2013).”
BackgroundResultLancet, J. E., Moseley, A. B., Coutre, S. E., DeAngelo, D. J., Othus, M. K. D., Tallman, M. S., Litzow, M. R., Komrokji, R. S., Erba, H. P., & Appelbaum, F. R. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001278 · Cited by 73
Acute promyelocytic leukemia: What is the new standard of care?
Watts, J. M., & Tallman, M. S. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.07.001 · Cited by 76
“More recently, Lo-Coco and coworkers conducted a randomized phase III trial showing that ATRA and ATO induction therapy followed by 4 cycles of ATRA/ATO consolidation in low- or intermediate-risk patients (WBC ≤ 10,000/μl) is highly effective and superior to ATRA/ chemotherapy-based induction, consolidation, and maint…”
BackgroundInfluentialClassification and risk assessment in AML: integrating cytogenetics and molecular profiling
Moarii, M., & Papaemmanuil, E. (2017) · Hematology · doi:10.1182/asheducation-2017.1.37 · Cited by 81
A TFIID-SAGA Perturbation that Targets MYB and Suppresses Acute Myeloid Leukemia
Xu, Y., Milazzo, J. P., Somerville, T. D. D., Tarumoto, Y., Huang, Y.-H., Ostrander, E. L., Wilkinson, J. E., Challen, G. A., & Vakoc, C. R. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.12.002 · Cited by 74
“Direct targeting of PML-RARA with all-trans retinoic acid and arsenic trioxide is curative in the subset of AML patients harboring this genetic alteration (Lo-Coco et al., 2013).”
BackgroundCurrent standard treatment of adult acute promyelocytic leukaemia
Lo‐Coco, F., Cicconi, L., & Breccia, M. (2015) · British Journal of Haematology · doi:10.1111/bjh.13890 · Cited by 72
Self-citationThrombosis and Hemostatic Abnormalities in Hematological Malignancies
Colombo, R., Gallipoli, P., & Castelli, R. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.05.003 · Cited by 73
Metabolic reprogramming and disease progression in cancer patients
Torresano, L., Nuevo‐Tapioles, C., Santacatterina, F., & Cuezva, J. M. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165721 · Cited by 75
Management of Hematologic Malignancies: Special Considerations in Pregnant Women
Amit, O., Barzilai, M., & Avivi, I. M. (2015) · Drugs · doi:10.1007/s40265-015-0464-0 · Cited by 70
“3rd trimesters) ABVD adriamycin, bleomycin, vinblastine, dacarbazine, ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, APL acute promyelocytic leukemia, ATRA all-trans retinoic acid, ATO arsenic trioxide, CHOP vincristine, doxorubicin, cyclophosphamide, prednisone, CLL chronic lymphocytic leukemia, CNS ce…”
BackgroundInfluentialZhu, H., Hu, J., Chen, L., Zhou, W., Li, X., Wang, L., Zhao, X., Zhang, Y., Zhao, H., Wang, A., et al. (2016) · Blood · doi:10.1182/blood-2016-02-699439 · Cited by 70
Induced protein degradation for therapeutics: past, present, and future
Yoon, H., Rutter, J. C., Li, Y.-D., & Ebert, B. L. (2024) · Journal of Clinical Investigation · doi:10.1172/jci175265 · Cited by 67
“Retinoids, including ATRA, are a mainstay treatment for APL, inducing degradation of the fusion protein, PML-RARA (104).”
InfluentialMcClellan, J. S., Dove, C. G., Gentles, A. J., Ryan, C. E., & Majeti, R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413383112 · Cited by 73
Pediatric Acute Myeloid Leukemia
Tarlock, K., & Meshinchi, S. (2014) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2014.09.007 · Cited by 83
Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review
Kadia, T. M., Ravandi, F., Cortes, J. E., & Kantarjian, H. M. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0617 · Cited by 103
The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives
Wu, Y., Zhang, C., Jiang, K., Werner, J., Bazhin, A. V., & D’Haese, J. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.621937 · Cited by 71
“Vitamin A derivatives: ATRA is a medication used for the treatment of acne and acute promyelocytic leukemia (174, 175).”
BackgroundPosttranslational modifications of RUNX1 as potential anticancer targets
Goyama, S., Huang, G., Kurokawa, M., & Mulloy, J. C. (2014) · Oncogene · doi:10.1038/onc.2014.305 · Cited by 75
Molecules that target nucleophosmin for cancer treatment: an update
Matteo, A. D., Franceschini, M., Chiarella, S., Rocchio, S., Travaglini‐Allocatelli, C., & Federici, L. (2016) · Oncotarget · doi:10.18632/oncotarget.8599 · Cited by 69
“All-trans-retinoic-acid (ATRA) (Figure 2E), alone or in combination with arsenic trioxide (ATO; As2O3), is currently the frontline treatment for acute promyelocytic leukemia (APL) harbouring the PMLRARα gene rearrangement [118, 119].”
BackgroundSu, M., Alonso, S., Jones, J. W., Yu, J., Kane, M. A., Jones, R. J., & Ghiaur, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127790 · Cited by 74
“While combinations of atRA with chemotherapy or arsenic trioxide eliminates MRD in APL and produces cures[21], understanding the mechanism responsible for persistence of MRD in APL patients treated with atRA monotherapy may have important implications for expanding atRA-based therapies to nonAPL AML.”
BackgroundGill, H., Yim, R., Lee, H. K. K., Mak, V., Lin, S., Kho, B., Yip, S., Lau, J. S. M., Li, W., Ip, H., et al. (2018) · Cancer · doi:10.1002/cncr.31327 · Cited by 67
“6) Leucocyte count >10 3 10(9)/L 14 10 7 4 Platelet count: Median (range), 310(9)/L 29 (6-162) 60.”
Cicconi, L., Platzbecker, U., Avvisati, G., Paoloni, F. P., Thiede, C., Vignetti, M., Fazi, P., Ferrara, F., Divona, M., Albano, F., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0589-3 · Cited by 73
Self-citationThe treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions
Iyer, S. G., Elias, L., Stanchina, M., & Watts, J. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1062524 · Cited by 70
“It is now known that low/intermediate-risk patients achieve excellent outcomes with chemotherapy-free ATRA/ATO-based consolidation following ATRA/ATO-based induction (5), and that high-risk patients who are successfully induced with ATRA/ATO with an anthracycline can be consolidated with ATRA/ATO with the omission of…”
BackgroundQuizartinib for the Treatment of FLT3/ITD Acute Myeloid Leukemia
Levis, M. J. (2014) · Future Oncology · doi:10.2217/fon.14.105 · Cited by 67
Persaud, S. D., Park, S. W., Ishigami‐Yuasa, M., Koyano‐Nakagawa, N., Kagechika, H., & Wei, L. (2016) · Scientific Reports · doi:10.1038/srep22396 · Cited by 77
Dobrotkova, V., Chlapek, P., Mazánek, P., Štěrba, J., & Veselská, R. (2018) · BMC Cancer · doi:10.1186/s12885-018-4966-5 · Cited by 73
Thomas, X. (2019) · Oncology and Therapy · doi:10.1007/s40487-018-0091-5 · Cited by 79
Tissue and serum metabolomic phenotyping for diagnosis and prognosis of hepatocellular carcinoma
Han, J. S., Han, M., Xing, H., Li, Z., Yuan, D., Wu, H., Zhang, H., Wang, M., Li, C., Liang, L., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32599 · Cited by 73
“According to a previous report, all-trans retinoic acid was observed to be effective for acute promyelocytic leukemia treatment in more than 90% of patients, leading to complete remission.(45) A previous study revealed that acyclic retinoid, a synthetic retinoid, suppressed Ras/MAP kinase signal transduction and resto…”
BackgroundGenome Sequencing during a Patient’s Journey through Cancer
Nangalia, J., & Campbell, P. J. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1910138 · Cited by 66
Targeted Therapy Alone for Acute Promyelocytic Leukemia
Lo‐Coco, F., Donato, L. D., & Schlenk, R. F. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1513710 · Cited by 66
Self-citationSIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
Yan, D., Franzini, A., Pomicter, A. D., Halverson, B. J., Antelope, O., Mason, C. C., Ahmann, J. M., Senina, A. V., Vellore, N. A., Jones, C. L., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0168 · Cited by 72
for the German-Austrian Acute Myeloid Leukemia Study Group, Schlenk, R. F., Lübbert, M., Benner, A., Lamparter, A., Krauter, J., Herr, W., Martin, H., Salih, H. R., Kündgen, A., et al. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2810-z · Cited by 66
“Based on the promising in vitro data, several clinical trials evaluated ATRA in combination with chemotherapy in nonAPL AML.”
BackgroundSelf-citationChinese Medicine in the Battle Against Obesity and Metabolic Diseases
Xu, L., Zhao, W., Wang, D., & Ma, X. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00850 · Cited by 68
“In the browning process, it has been shown that curcumin treatment induces browning in primary white adipocytes and adipose tissues and augments thermogenic and mitochondrial gene programs in a classic norepinephrine dependent manner (Wang et al., 2015; Lone et al., 2016).”
BackgroundTherapy-related myeloid neoplasms: does knowing the origin help to guide treatment?
Heuser, M. (2016) · Hematology · doi:10.1182/asheducation-2016.1.24 · Cited by 70
Yang, M., Wan, W., Luo, J., Zheng, M., Huang, K., Yang, L., Mai, H., Li, J., Chen, H. Q., Sun, X., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25271 · Cited by 64
“Median platelets, ×10(9)/L (range) 19 (4-226) 23 (4-82) 17 (4-226) .”
The impact of workplace harassment and domestic violence on work outcomes in the developing world
Węziak‐Białowolska, D., Białowolski, P., & McNeely, E. (2019) · World Development · doi:10.1016/j.worlddev.2019.104732 · Cited by 76
Russell, N. H., Burnett, A. K., Hills, R. K., Betteridge, S., Dennis, M., Jovanovic, J. V., Dillon, R. J., & Grimwade, D. J. (2018) · Blood · doi:10.1182/blood-2018-05-851824 · Cited by 62
Zhang, X., Hu, B., Sun, Y., Huang, X., Cheng, J., Huang, A., Zeng, H., Qiu, S., Cao, Y., Fan, J., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.335 · Cited by 64
A review of arsenic trioxide and acute promyelocytic leukemia.
Alimoghaddam, K. (2014) · Europe PMC (PubMed Central) · Cited by 62
Drug-induced liver injury in Oncology
Ricart, A. D. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx158 · Cited by 64
“Liver tests elevations are usually asymptomatic and transient, with dose adjustment or drug discontinuation rarely required [66].”
BackgroundAutophagy in cancer: a complex relationship
Wilde, L. R., Tanson, K., Curry, J., & Martinez‐Outschoorn, U. (2018) · Biochemical Journal · doi:10.1042/bcj20170847 · Cited by 66
Recent advances in the understanding and treatment of acute myeloid leukemia
Watts, J. M., & Nimer, S. D. (2018) · F1000Research · doi:10.12688/f1000research.14116.1 · Cited by 68
Current views on the genetic landscape and management of variant acute promyelocytic leukemia
Zhang, X., Sun, J., Yu, W., & Jin, J. (2021) · Biomarker Research · doi:10.1186/s40364-021-00284-x · Cited by 69
Biological and environmental hazards associated with exposure to chemical warfare agents: arsenicals
Li, C., Srivastava, R. K., & Athar, M. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13214 · Cited by 62
Metformin ameliorates arsenic trioxide hepatotoxicity via inhibiting mitochondrial complex I
Ling, S., Shan, Q., Liu, P., Feng, T., Zhang, X., Xiang, P., Chen, K., Xie, H., Song, P., Zhou, L., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.482 · Cited by 65
“grade 3–4 liver toxicity was found in 25–63% of patients treated with ATO and all trans retinoic acid.(8,9) Metformin, a first line oral hypoglycemic drug for type 2”
BackgroundPoiré, X., Moser, B. K., Gallagher, R. E., Laumann, K. M., Bloomfield, C. D., Powell, B. L., Koval, G., Gulati, K., Holowka, N., Larson, R. A., et al. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.842985 · Cited by 60
Lehmann, S., Deneberg, S., Antunović, P., Derolf, Å. R., Garelius, H. G., Lazarević, V., Myhr‐Eriksson, K., Möllgård, L., Uggla, B., Wåhlin, A., et al. (2017) · Leukemia · doi:10.1038/leu.2017.71 · Cited by 60
Chen, L., Zhu, H., Li, Y., Liu, Q.-F., Hu, Y., Zhou, J.-F., Jin, J., Hu, J.-D., Liu, T., Wu, D., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2020382118 · Cited by 62
Sidhom, J.-W., Siddarthan, I. J., Lai, B.-S., Luo, A., Hambley, B. C., Bynum, J. P., Duffield, A. S., Streiff, M. B., Moliterno, A. R., Imus, P. H., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00179-y · Cited by 61
Honokiol Induces Ferroptosis by Upregulating HMOX1 in Acute Myeloid Leukemia Cells
Lai, X., Sun, Y., Zhang, X., Wang, D., Wang, J., Wang, H., Zhao, Y., Liu, X., Xu, X., Song, H., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.897791 · Cited by 63
“For example, arsenic trioxide combined with all-trans retinoic acid can achieve a complete response in 90–100% of acute promyelocytic leukemia (APL) patients, with an overall survival rate of 86–97% (Lo-Coco et al., 2013; Ni et al., 2019).”
BackgroundShinagawa, K., Yanada, M., Sakura, T., Ueda, Y., Sawa, M., Miyatake, J., Dobashi, N., Kojima, M., Hatta, Y., Emi, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.3570 · Cited by 61
Toward the potential cure of leukemias in the next decade
Kantarjian, H. M., Keating, M. J., & Freireich, E. J. (2018) · Cancer · doi:10.1002/cncr.31669 · Cited by 56
“The superiority of the nonchemotherapy ATRA plus ATO regimen over the then-standard of care ATRA plus idarubicin regimen in patients with lower risk APL was established in a randomized trial conducted by Italian-German investigators.(23,24) This was later confirmed across APL risk groups by British and Spanish investi…”
NOX2-Derived Reactive Oxygen Species in Cancer
Wiktorin, H. G., Aydin, E., Hellstrand, K., & Martner, A. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/7095902 · Cited by 66
“ATRA releases this block and allows the differentiation of immature leukemic promyelocytes into mature granulocytes [204].”
BackgroundOrfali, N. M., O’Donovan, T. R., Nyhan, M. J., Britschgi, A., Tschan, M. P., Cahill, M. R., Mongan, N. P., Gudas, L. J., & McKenna, S. L. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.04.012 · Cited by 67
“When administered in combination with ATRA, ATO eliminates the need for cytotoxic chemotherapy in the treatment of low to intermediate-risk APL [7].”
Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia
Schlenk, R. F., & Döhner, H. (2013) · Hematology · doi:10.1182/asheducation-2013.1.324 · Cited by 85
“‡Three or more chromosome abnormalities in the absence of one of the WHOdesignated recurring translocations or inversions: t(15;17), t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23), t(6;9), inv(3), or t(3;3).”
BackgroundInfluentialSelf-citationBaik, H., Boulanger, M., Hosseini, M., Kowalczyk, J., Zaghdoudi, S., Salem, T., Sarry, J., Hicheri, Y., Cartron, G., Piechaczyk, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3361 · Cited by 61
Progresses and emerging trends of arsenic research in the past 120 years
Li, C., Wang, J., Yan, B., Miao, A., Zhong, H., Zhang, W., & Ma, L. Q. (2020) · Critical Reviews in Environmental Science and Technology · doi:10.1080/10643389.2020.1752611 · Cited by 59
ASGARD is a single-cell guided pipeline to aid repurposing of drugs
He, B., Xiao, Y., Liang, H., Huang, Q., Du, Y., Li, Y., Garmire, D., Sun, D., & Garmire, L. X. (2023) · Nature Communications · doi:10.1038/s41467-023-36637-3 · Cited by 57
Metadata
- Authors
- Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., Specchia, G., Sica, S., Divona, M., Levis, A., Fiedler, W., Cerqui, E., Breccia, M., Fioritoni, G., Salih, H. R., Cazzola, M., Melillo, L., Carella, A. M., Brandts, C. H., Morra, E., von Lilienfeld-Toal, M., Hertenstein, B., Wattad, M., Lübbert, M., Hänel, M., Schmitz, N., Link, H., Kropp, M. G., Rambaldi, A., La Nasa, G., Luppi, M., Ciceri, F., Finizio, O., Venditti, A., Fabbiano, F., Döhner, K., Sauer, M., Ganser, A., Amadori, S., Mandelli, F., Döhner, H., Ehninger, G., Schlenk, R. F., & Platzbecker, U.
- ORCID
- Avvisati, Giuseppe
- Vignetti, Marco
- Thiede, Christian
- Iacobelli, Simona
- Ferrara, Felicetto
- Fazi, Paola
- Cicconi, Laura
- Specchia, Giorgina
- Sica, Simona
- Fiedler, Walter
- Breccia, Massimo
- Salih, Helmut R.
- Cazzola, Mario
- Melillo, Lorella
- Carella, Angelo M.
- Brandts, Christian H.
- Hertenstein, Bernd
- Lübbert, Michael
- Hänel, Matthias
- Schmitz, Norbert
- Link, Hartmut
- Rambaldi, Alessandro
- Luppi, Mario
- Ciceri, Fabio
- Finizio, Olimpia
- Venditti, Adriano
- Döhner, Konstanze
- Ganser, Arnold
- Amadori, Sergio
- Döhner, Hartmut
- Ehninger, Gerhard
- Schlenk, Richard F.
- Platzbecker, Uwe
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-11
- Volume
- 369
- Issue
- 2
- Pages
- 111-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2129338773
- Cited by
- 1,611
- References
- 42
- Citations by year
- 2026: 83 · 2025: 89 · 2024: 132 · 2023: 144 · 2022: 110 · 2021: 147 · 2020: 137 · 2019: 125 · 2018: 122 · 2017: 107 · 2016: 117 · 2015: 144 · 2014: 119 · 2013: 33
- FWCI
- 61.62
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- acute promyelocytic leukemia, all-trans retinoic acid, arsenic trioxide, idarubicin, induction therapy, consolidation therapy, maintenance therapy, event-free survival, overall survival, complete remission, hematologic toxicity, hepatotoxicity
- MeSH terms
- Arsenic Trioxide, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Arsenicals, Female, Humans, Male, Middle Aged, Neutropenia, Oxides, Thrombocytopenia, Tretinoin, Leukemia, Promyelocytic, Acute, Disease-Free Survival, Young Adult, Maintenance Chemotherapy, Induction Chemotherapy, Consolidation Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.